Daily Roundup

ALC.ASX EGH.ASX ATG.ASX SND.ASX CU6.ASX

Alcidion Group Delivers Strong Q2 Results

Alcidion Group Ltd (ASX:ALC) has reported impressive Q2 FY26 results, including significant new contract wins and expansions. The company was selected as the preferred supplier for the University Hospitals Sussex NHS Foundation Trust's new Electronic Patient Record solution, with a total contract value expected to be at least $35 million.

In the quarter, Alcidion achieved new total contract value sales of $15.4 million, including a $12.3 million expansion for additional software modules from Miya Precision to enable Leidos to deliver further solution components to the Commonwealth of Australia. The company also secured several existing contract renewals.

Alcidion's FY26 contracted revenue is now up 40% compared to the prior year, and the company expects a material uplift in H2 FY26 customer receipts. Looking ahead, Alcidion expects its FY26 EBITDA and cash flow to be at least in line with FY25, with potential upside from the successful completion of the University Hospitals Sussex contract and continued conversion of new revenue opportunities.

Eureka Expands Footprint with Nagambie Lifestyle Park Acquisition

Eureka Group Holdings Ltd (ASX:EGH) has executed contracts to acquire Nagambie Lifestyle Park, a mixed-use residential community located about 140km north of Melbourne. The $11 million acquisition represents Eureka's second All Age Rental Village in Victoria and includes 127 revenue-generating sites, such as land-lease homes, park-owned rentals, annual sites, and motel rooms.

The purchase price reflects an ingoing yield of 7.3% and a target five-year IRR of 15.9%. Eureka plans to reactivate the planning permit and, subject to Council approval, anticipate landing new homes at the park from mid-2026. Upon final build-out, Eureka expects Nagambie Lifestyle Park to comprise a community of 155 sites, with more than 90% being long-term rental units and land-lease homes.

Articore Group Delivers Margin Expansion and Improved Revenue

Articore Group Ltd (ASX:ATG) has reported clear progress against its turnaround strategy in the first half of FY26. The company's marketplace revenue decline slowed to 3.2% in 2Q, an improvement from the 6.6% decline in 1Q.

Articore's 1HFY26 gross profit increased 6.0%, driven by supply chain synergies and new artist account fees. The company also saw an 8.9% rise in 1HFY26 gross profit after paid acquisition, due to higher gross profit and improved efficiency in paid marketing.

The Group CEO and Managing Director stated that these results reflect disciplined execution and a structural step-change in the company's operations, and Articore is confident it can build on the momentum as it enters 2026.

Saunders Secures $16.4M Energy Contract with Ampol

Saunders International Limited (ASX:SND) has announced a $16.4 million project at Ampol's Lytton Refinery in Brisbane. The project scope includes the renewal and refurbishment of an existing fuel storage tank, supporting Ampol's ongoing investment in upgrading and future-proofing critical refinery infrastructure.

The award was made under Saunders' Master Services Agreements with long-term client Ampol, further reinforcing the strength of the relationship and Saunders' position as a trusted delivery partner in the Energy market. The project is expected to contribute to Saunders' revenue and earnings in FY26 and FY27.

Clarity Pharmaceuticals' SECuRE Trial Continues with Positive Interim Results

Clarity Pharmaceuticals Ltd (ASX:CU6) has announced that the SECuRE trial for its 67Cu-SAR-bisPSMA product will continue with no modifications to the protocol following a favorable interim data review by the Safety Review Committee.

The interim assessment included data from nine participants in the Cohort Expansion Phase (Phase II) of the trial, with the results demonstrating a favorable safety profile and promising efficacy, including six out of the nine participants showing PSA reductions of 50% or more. Clarity is also progressing plans for a Phase III registrational trial based on the data generated to date.